Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Baxter operates in three primary segments: BioScience (recombinant and plasma-based proteins), Medication Delivery (IV solutions, infusion pumps, anesthesia), and Renal (dialysis products). The company is a large accelerated filer headquartered in Deerfield, Illinois.
Key Financial Metrics
| Metric (in millions) | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $2,824 | $2,877 |
| Gross Margin | $1,488 (52.7%) | $1,380 (48.0%) |
| Net Income (Attributable to Baxter) | $516 | $429 |
| Diluted EPS | $0.83 | $0.67 |
| Cash Flow from Operations | $237 | $362 |
| Cash and Equivalents (Ending) | $1,703 | $1,736 |
| Total Debt (Short-term + Long-term) | $3,910 | $3,756 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2% to $2.824 billion. This decline was driven by an 8 percentage point unfavorable foreign currency impact due to a stronger U.S. Dollar. Excluding currency effects, sales increased across most product lines.
- Profitability: Net income increased 20% to $516 million. This improvement was primarily due to a 4.7 percentage point increase in gross margin (driven by sales mix and yield improvements) and the absence of significant charges that impacted Q1 2008.
- Segment Performance:
- BioScience: Sales up 3%; Pre-tax income up 2%.
- Medication Delivery: Sales down 3%; Pre-tax income up 79% (Q1 2008 included $72 million in charges for COLLEAGUE pumps and heparin recalls).
- Renal: Sales down 8%; Pre-tax income down 36% due to lower saline sales and increased R&D costs.
- Cash Flow: Operating cash flow decreased to $237 million from $362 million, despite higher earnings, due to a $100 million discretionary pension contribution and timing of working capital payments.
Guidance, Outlook, and Risks
- Outlook: Management anticipates a full-year 2009 effective tax rate of approximately 18.5% to 19.0%, excluding special items.
- Regulatory Matters (COLLEAGUE Pumps): Baxter continues to hold shipments of COLLEAGUE infusion pumps in the U.S. pending FDA approval of a remediation plan. A $107 million reserve remains for cash costs related to these pumps. Additional charges may be required based on future dialogue with the FDA.
- Regulatory Matters (Heparin): The company recorded a $19 million charge in 2008 for heparin recalls. Approximately 135 lawsuits remain pending regarding adverse reactions.
- Legal Proceedings: Significant litigation includes patent disputes over sevoflurane (favorable rulings in U.S. and Europe; injunction lifted in Japan) and hemodialysis patents against Fresenius. A class action settlement regarding Medicare/Medicaid pricing is expected to receive final approval in Q2 2009.
- Subsequent Event: On April 14, 2009, Baxter entered an exclusive distribution agreement with SIGMA International for infusion pumps, paying $100 million upfront and acquiring a 40% equity stake.
- Capital Allocation: The company repurchased 10.1 million shares for $566 million in Q1 2009. $600 million remains available under the current buyback authorization.
Investor Verification Checklist
- COLLEAGUE Pump Resolution: Verify the status of FDA reviews and the potential for additional charges beyond the $107 million reserve.
- Foreign Currency Impact: Assess the sensitivity of future earnings to U.S. Dollar strength, which negatively impacted Q1 sales by 8 percentage points.
- Legal Settlements: Monitor the final approval of the Medicare/Medicaid pricing settlement and outcomes of the Fresenius hemodialysis litigation.
- Debt Structure: Review the impact of the new $350 million senior unsecured notes issued in February 2009 on future interest expenses.
- Stock Repurchases: Confirm the remaining $600 million authorization and the company's commitment to capital returns amidst market volatility.